Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $250.73, along with a high estimate of $300.00 and a low estimate of $170.00. A negative ...

Following promising phase 1 data, TCMCB07 is being further evaluated in a phase 2 trial for the treatment of patients with ...

Barclays analyst Tom O’Malley lowered the firm’s price target on Analog Devices (ADI) to $170 from $240 and keeps an Equal Weight rating on the ...

On May 20, 1875, delegates from a group of 17 countries gathered in Paris to sign what may be the most overlooked yet ...

With Huang and Szeto's leadership, EnCharge is well-positioned to continue strengthening its organizational foundation and attracting world-class talent, as it scales its portfolio of innovative ...